ArticleFrontiers in immunology2022

Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.

Hongwei Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.